Ebola Cluster Traced to Vaccinated Taxi Driver Who Appeared to Recover Ebola Cluster Traced to Vaccinated Taxi Driver Who Appeared to Recover
This is the story of a taxi driver, a vaccine that may not live up to its billing, and a treatment that seemed to save him from death, only to set the stage for his infection to spread to 91 others in six communities over 4 months.Reuters Health Information (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - April 1, 2021 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news

Getting One Vaccine Is Good. How About Mix-and-Match?
Researchers are exploring the possible benefits of pairing doses from two different Covid-19 vaccines. (Source: NYT Health)
Source: NYT Health - March 30, 2021 Category: Consumer Health News Authors: Carl Zimmer Tags: your-feed-science Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Immune System Proteins Ebola Virus AstraZeneca PLC Gamaleya Research Institute of Epidemiology and Microbiology Pfizer Inc Great Britain Russia Source Type: news

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, NJ (March 29, 2021) - Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union’s 55 member states with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful appr...
Source: Johnson and Johnson - March 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Statement on the Interim SAGE Recommendation Supporting the Use of the Johnson & Johnson COVID-19 Vaccine
New Brunswick, NJ (March 17, 2021) – We welcome the interim recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the World Health Organization (WHO) supporting the use of Johnson & Johnson’s single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in persons aged 18 years and above. SAGE advises WHO on global vaccine and immunization policies and its recommendations for use provide guidance on the use of vaccines supplied through the COVAX Facility, a global risk-sharing mechanism for pooled procurement and ...
Source: Johnson and Johnson - March 17, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
NEW BRUNSWICK, N.J., March 12, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants give...
Source: Johnson and Johnson - March 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. The CMA follows a Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).2 The CMA is valid in all 27 member states of the European Union (EU), plus Norway, Iceland and Liechtenstei...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion to recommend the Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percen...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

1,600 vaccinated in Guinea Ebola virus outbreak but more jabs needed: WHO
More than 1,600 people have received Ebola virus vaccinations in Guinea where four have died in a new outbreak, but more lifesaving jabs will be needed to contain the disease, the World Health Organization (WHO) said on Friday. (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - March 5, 2021 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use
March 5, 2021 - Johnson & Johnson (the Company) announced today that Health Canada has granted an Interim Order (IO) authorization for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.This decision was based on scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.Johnson & Johnson anticipa...
Source: Johnson and Johnson - March 5, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Another Covid-19 Threat: Health Care Workers Under Attack
A healthcare worker at a testing facility collects samples for the coronavirus at Mimar Sinan State Hospital, Buyukcekmece district in Istanbul, Turkey. Credit: UNDP Turkey/Levent KuluBy Joe Amon and Christina WillePHILADELPHIA, US, Mar 3 2021 (IPS) In the first months of the COVID-19 pandemic, at a certain hour of the evening, people in cities around the world opened their windows or stood on their rooftops and banged pots and rang bells. As the coronavirus spread and the number of deaths mounted, it was a moment for people distancing themselves from others to show solidarity and appreciation for the heroic work of health...
Source: IPS Inter Press Service - Health - March 3, 2021 Category: International Medicine & Public Health Authors: Joe Amon and Christina Wille Tags: Global Headlines Health TerraViva United Nations Source Type: news

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection agai...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., February 26, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial. “We are e...
Source: Johnson and Johnson - February 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Guinea: Hundreds of People Vaccinated Against Ebola
[RFI] More than 200 people in Guinea have been vaccinated against Ebola, just days after the arrival of some 11,000 doses of the Merck vaccine and just over a week since the West African country declared its first Ebola outbreak since the deadly epidemic from 2014 to 2016. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 26, 2021 Category: African Health Source Type: news

Guinea: Vital Ebola Vaccines Arrive After Dust Storm Delay
[RFI] Health officials are heading directly to Guinea's southeast region on Tuesday, after a special plane with 11,000 doses of Ebola vaccine landed late Monday night. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 23, 2021 Category: African Health Source Type: news

Guinea: Threat of Double Epidemic Worries Guineans As Ebola Vaccines Dispatched
[RFI] Some 11,000 vaccines for the Ebola virus are expected to arrive in Guinea this weekend, as a new outbreak has left five people dead and almost 200 contact cases. The stark reminder of the last West African outbreak comes with added complications of the Covid-19 crisis, which is already creating new challenges for health workers. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 20, 2021 Category: African Health Source Type: news

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 19, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered today includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Company’s rolling submission of clinical data to WHO is now complete.“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our u...
Source: Johnson and Johnson - February 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 16, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen-Cilag International N.V., has submitted a conditional Marketing Authorisation Application (cMAA) to the European Medicines Agency (EMA) seeking authorisation for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial.“Throughout Europe, there remains an urgent need for additional COVID-19 vaccines, and today’s submission is a significant step forward in ensuring the European Un...
Source: Johnson and Johnson - February 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Guinea Declares Ebola Epidemic as Neighboring Countries Act to Prevent Further Spread
DAKAR, Senegal — Guinea has officially declared it has an Ebola epidemic after at least three people have died and four others have been infected in the West African nation. Neighboring Sierra Leone and Liberia have put their citizens on high alert as the three West African nations battled the world’s deadliest Ebola outbreak from 2014 to 2016, which began in Guinea and in which more than 11,300 people died. Sierra Leone’s President Julius Maada Bio has flown to consult with Guinean President Alpha Conde. Guinea’s new Ebola outbreak occurred in N’Zerekore, in southern Guinea, where health offi...
Source: TIME: Health - February 16, 2021 Category: Consumer Health News Authors: CARLEY PETESCH / AP Tags: Uncategorized Source Type: news

Guinea tracks potential Ebola contacts as vaccination campaign begins in Congo
Guinea is tracking down people who potentially came in contact with Ebola patients after three people died of the disease, Health Minister Remy Lamah said on Monday. Meanwhile, the WHO said an Ebola vaccination campaign has begun in the Congolese city of Butembo. (Source: CBC | Health)
Source: CBC | Health - February 15, 2021 Category: Consumer Health News Tags: News/World Source Type: news

Africa: Organisations Announce Global Ebola Vaccine Stockpile for Quick Response
[WHO] The four leading international health and humanitarian organizations announced today the establishment of a global Ebola vaccine stockpile to ensure outbreak response. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 14, 2021 Category: African Health Source Type: news

COVID-19 Pandemic has Shown Humanity at its Best – & at its Worst
A health worker at a local health centre in Kinshasa, Democratic Republic of the Congo, prepares a vaccine injection. The dispatch of millions of COVID-19 vaccines to Africa started in February. Credit: UNICEF/Sibylle DesjardinsBy Tedros Adhanom GhebreyesusGENEVA, Feb 11 2021 (IPS) WHO and UNICEF have a long, deep and very special relationship. Neither of us could do what we do without the other. UNICEF’s success is WHO’s success, and we are proud to be your partner on so many issues: Ebola, polio, maternal health, nutrition, infection prevention and control, primary health care – the list is long. Neve...
Source: IPS Inter Press Service - Health - February 11, 2021 Category: International Medicine & Public Health Authors: Tedros Adhanom Ghebreyesus Tags: Development & Aid Education Global Globalisation Headlines Health Inequity Poverty & SDGs TerraViva United Nations Source Type: news

Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 4, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The Company’s EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose vaccine met all primary and key secondary endpoints. The Company expects to have product available to ship immediately followi...
Source: Johnson and Johnson - February 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

NIH Director Francis Collins Is Fighting This Coronavirus While Preparing for the Next One
In May 2020, Dr. Francis Collins, the longtime head of the National Institutes of Health (NIH), was called to the White House to meet with Jared Kushner, the then President’s son-in-law and adviser, and Dr. Deborah Birx, the head of the White House Coronavirus Task Force. A few weeks earlier, Congress had given the NIH $1.5 billion to try to speed up the process of developing new diagnostic tests for COVID-19, and the White House, which was dubious about increasing the rate of testing, wanted to know more about what the NIH was doing. Collins is technically the boss of Dr. Anthony Fauci, but during the pandemic he ha...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe CO...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, wit...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Antibody highs and lows in survivors of Ebola
(University of Liverpool) A high proportion of survivors of Ebola experienced a resurgence in antibody levels nearly a year after recovery, a new University of Liverpool study has found. Published today in Nature, the finding hints that hidden reservoirs of virus could exist long after symptoms ease and has implications for monitoring programmes and vaccine strategies. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 27, 2021 Category: Infectious Diseases Source Type: news

Merck Stops Developing Both Of Its COVID-19 Vaccine Candidates
Merck, which previously made an Ebola vaccine, had been seen as a serious contender in the worldwide race to come up with an answer to the coronavirus.(Image credit: Budrul Chukrut/SOPA Images/LightRocket via Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - January 25, 2021 Category: Consumer Health News Authors: Bill Chappell Source Type: news

Johnson & Johnson ’s 1-Shot COVID-19 Vaccine Shows Promise in Early-Stage Trials
Johnson & Johnson’s experimental one-shot Covid-19 vaccine generated a long-lasting immune response in an early safety study, providing a glimpse at how it will perform in the real world as the company inches closer to approaching U.S. regulators for clearance. More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report, and all participants formed the antibodies within 57 days. The immune response lasted for the full 71 days of the trial. “Looking at the antibodies, there should be good hope and good reason that the va...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Riley Griffin / Bloomberg Tags: Uncategorized COVID-19 overnight wire Source Type: news

Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
January 13, 2021 -- Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.The Phase 1/2a interim analysis showed that the Company’s COVID-19 vaccine candidate induced a...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

WHO and Partners to Stockpile Ebola Vaccine
TUESDAY, Jan. 12, 2021 -- Ebola vaccines are being stockpiled by the World Health Organization and other groups to combat future outbreaks of the deadly disease. An emergency reserve of about 500,000 doses of a Merck vaccine will be established,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Africa: UN Agencies, Partners Establish Global Ebola Vaccine Stockpile
[UN News] In a major milestone in the fight against deadly diseases, United Nations agencies and humanitarian partners announced on Tuesday, the establishment of a global Ebola vaccine stockpile, to help control future epidemics by ensuring timely access to vaccines for populations at risk, during outbreaks. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 12, 2021 Category: African Health Source Type: news

Ebola vaccines stockpiled against future outbreaks
The World Health Organization and partners say they are creating a global stockpile of Ebola vaccines to help stamp out future outbreaks (Source: ABC News: Health)
Source: ABC News: Health - January 12, 2021 Category: Consumer Health News Tags: Health Source Type: news

UN agencies, partners establish global Ebola vaccine stockpile
In a major milestone in the fight against deadly diseases, United Nations agencies and humanitarian partners announced on Tuesday, the establishment of a global Ebola vaccine stockpile, to help control future epidemics by ensuring timely access to vaccines for populations at risk, during outbreaks.  (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - January 12, 2021 Category: International Medicine & Public Health Source Type: news

UN agencies and partners establish global Ebola vaccine stockpile
In a major milestone in the fight against deadly diseases, United Nations agencies and humanitarian partners announced on Tuesday, the establishment of a global Ebola vaccine stockpile, to help control future epidemics by ensuring timely access to vaccines for populations at risk, during outbreaks.  (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - January 12, 2021 Category: International Medicine & Public Health Source Type: news

The Oxford-AstraZeneca Vaccine Approval May Be the Most Globally Important Yet
The COVID-19 vaccine developed by the University of Oxford and AstraZeneca wasn’t the first to be OK’d by regulators in the U.K.—health officials authorized the Pfizer-BioNTech jab nearly four weeks earlier. And it’s not the most effective—Stage 3 clinical trials suggest it prevents COVID-19 symptoms about 70% of the time vs. about 95% for the Pfizer vaccine and a similar one from Moderna (which is authorized in the U.S., but not the U.K.). But the greenlight from the British Medicines and Healthcare Products Regulatory Agency on Wednesday could be a big step toward bringing the COVID-19 pande...
Source: TIME: Health - December 30, 2020 Category: Consumer Health News Authors: Michael Zennie Tags: Uncategorized COVID-19 Explainer overnight Source Type: news

Why Africa ’s COVID-19 Outbreak Hasn’t Been as Bad as Everyone Feared
When COVID-19 initially blazed through Asia, Europe and then the United States, global public health experts worried that it could be catastrophic for Africa, with its crowded cities, poorly funded health sector and lack of testing facilities. The U.N. Economic Commission for Africa in April predicted up to 300,000 deaths this year if the virus couldn’t be contained on the continent. Yet it was the U.S, with its superior health system, that hit that grim milestone first, and so far, Africa has been largely spared the worst of the devastation experienced by the rest of the world. As of Dec. 29, the Africa Centres for ...
Source: TIME: Health - December 30, 2020 Category: Consumer Health News Authors: Aryn Baker Tags: Uncategorized COVID-19 Londontime Source Type: news

Uganda: Is Uganda Ready to Acquire the Covid-19 Vaccine?
[Monitor] The world's population, years over, has been affected by a number of viral diseases such a Ebola and Influenza which, in some cases, have caused millions of deaths. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 21, 2020 Category: African Health Source Type: news

Top Global Health Moments of 2020
By The Editorial Team, IntraHealth International Community Health Nurse Olivia Yeboah thoroughly washes her hands at the Akropong Clinic in Ghana. Photo by Emmanuel Attramah, PMI Impact Malaria/US President's Malaria Initiative.December 17, 2020If we wanted to, we could list a COVID-19 moment for every month of 2020.  We all know that the onset of the coronavirus pandemic—first in China and then worldwide—overwhelmed news coverage this year. And with good reason. It’s the first large-scale global pandemic in 100 years. At the time this article was publ...
Source: IntraHealth International - December 17, 2020 Category: International Medicine & Public Health Authors: kseaton Tags: HIV & AIDS COVID-19 Nutrition Policy Advocacy Health Workforce Systems Nursing Midwifery 2020 Health Workers Source Type: news

We All Deserve Protection From Covid-19
Credit: United NationsBy Adaora OkoliNEW ORLEANS, US, Dec 11 2020 (IPS) When I contracted Ebola virus disease in August 2014 while working as a medical doctor in a well-known private hospital in Lagos, Nigeria, I was denied access to a potential cure. For 15 days, I battled for my life in a debilitated isolation ward, not knowing if I would survive. But American aid workers who contracted Ebola were administered Zmapp, a monoclonal antibody treatment, which reduces the relative risk of death from Ebola by 40% as well as shorten the duration of stay in the Ebola treatment units. They survived. We were told that Zmapp was e...
Source: IPS Inter Press Service - Health - December 11, 2020 Category: International Medicine & Public Health Authors: Adaora Okoli Tags: Headlines Health TerraViva United Nations Source Type: news

Even the Pandemic Hasn ’t Made Public-Health Icon Paul Farmer Lose Hope
“Am I allowed to be a normal human and say, ‘How are you?'” asks Dr. Paul Farmer as soon as our Zoom call connects. It’s an apt introduction for a man who became a living legend in the global health world mostly by being a normal human who does extraordinary things–starting with co-founding the Boston-based nonprofit organization Partners in Health (PIH) in 1987, before graduating from Harvard Medical School. Since then, PIH and its global staff of 18,000 have helped strengthen health systems in the “clinical deserts” of Haiti, Rwanda, Peru, Russia and numerous other countries. PIH...
Source: TIME: Health - December 3, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Magazine Public Health Second click Source Type: news

Cutting UK overseas aid could harm the fight against future pandemics | Matthew Baylis and Fiona Tomley
In our age of emerging pathogens, funding for global research into zoonotic diseases such as Covid-19, Ebola and Sars is vitalCoronavirus – latest updatesSee all our coronavirus coverageThis year, we ’ve seen how a previously unknown animal virus can spill over into the human population in one country, pass rapidly between people, and spread across the world in days. With nearly1.5m reported deaths from Covid-19, the virus is a startling indication of how the health of the world ’s human population is inseparable from animals and the environment that we share with them.Treating health in a way that recogn...
Source: Guardian Unlimited Science - December 2, 2020 Category: Science Authors: Matthew Baylis and Fiona Tomley Tags: Vaccines and immunisation Coronavirus Infectious diseases Microbiology Science Health World news Society Medical research Ebola Sars Aid UK news Source Type: news

Janssen's Two-Dose Ebola Vaccine Appears Safe, Immunogenic in HIV-Infected Patients Janssen's Two-Dose Ebola Vaccine Appears Safe, Immunogenic in HIV-Infected Patients
Janssen's two-dose Ebola vaccine appears to be safe for HIV-infected patients and provokes an immune response, although one that initially is not as strong as in HIV-negative patients, according to new research.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 2, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Japan Should Lead Charge for Equitable Access to COVID-19 Vaccines
Credit: United NationsBy Cecilia RussellJOHANNESBURG, South Africa, Nov 20 2020 (IPS) Japan should step up and play a role as a global facilitator for equitable access to COVID-19 vaccines, Dr Daisaku Higashi said at a recent Japan Parliamentarians Federation for Population (JPFP) study meeting. The country should use the credibility developed in the post-Second World War era as a country with expertise in peacebuilding to ensure that developing countries are included in the vaccines’ rollout. Higashi, a renowned commentator from Sophia University, warned that only an international effort could solve the problems ca...
Source: IPS Inter Press Service - Health - November 20, 2020 Category: International Medicine & Public Health Authors: Cecilia Russell Tags: Aid Asia-Pacific Development & Aid Economy & Trade Featured Global Headlines Health Humanitarian Emergencies TerraViva United Nations Asian Population and Development Association (APDA) Source Type: news

Third Covid-19 candidate vaccine developed by Janssen Pharmaceutical Companies will be tested in clinical trials involving patients in the UK
Phase 3 placebo controlled RCT will involve 30,000 patients and assess a two dose regimen of the vaccine 57 days apart, using the same human adenovirus that provided the vector for Janssen's Ebola virus vaccine. A trial of a single dose by Janssen is already underway in the US. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 18, 2020 Category: Consumer Health News Source Type: news

Covid: 6,000 UK volunteers to be injected with vaccine in phase 3 trial
Third vaccine to undergo large-scale clinical testing in Britain has been modelled on Ebola jabCoronavirus – latest updatesSee all our coronavirus coverageSix thousand British volunteers are to be injected with an experimental Covid vaccine modelled on an Ebola jab.It is the third Covid vaccine to enter large-scale clinical trials in the UK. Pursuing multiple candidates is essential to guarantee UK supply and ensure that most effective vaccine is identified, researchers stressed.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 16, 2020 Category: Science Authors: Linda Geddes Tags: Coronavirus Vaccines and immunisation Health Infectious diseases Medical research UK news Alok Sharma Science Source Type: news

Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate
November 15, 2020 -- The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enroll and vaccinate study participants. ENSEMBLE is proceeding to enroll up to 60,000 participants worldwide.In addition to the single-dose regimen ENSEMBLE study, Janssen has now initiated the two-dose regimen ENSEMBLE 2 trial. ENSEMBLE 2 is a complementary, planned, pivotal, large-scale, multi-country Phase 3 trial that will study the safety and efficacy of a two-dose ...
Source: Johnson and Johnson - November 16, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Why You May Not Be Able to Get Pfizer ’s Frontrunner COVID-19 Vaccine
The freezer in your kitchen likely gets down to temperatures around -20° C (-4° F). “That keeps your ice cream cold, but it doesn’t turn your ice cream into an impenetrable block of ice,” says Paula Cannon, an associate professor of molecular microbiology and immunology at the University of Southern California’s Keck School of Medicine. Pfizer’s promising COVID-19 vaccine, by contrast, must be stored at about -70° C (-94° F)—a temperature cold enough to harden ice cream into a spoon-breaking block of ice, and that only specialized freezers can produce. Those cold storage ...
Source: TIME: Health - November 13, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news

COMMENTARY: The Sinatra Doctrine Confronts a Global Consensus
A photo-collage. Credit: Peter Costantini.By Peter CostantiniSEATTLE, Oct 23 2020 (IPS) By late September, the COVID-19 pandemic in the United States had claimed 200,000 lives. That’s equivalent to a slightly higher toll than the 418,500 United States deaths in World War II, adjusted for relative population and duration. [See note below.] With four percent of the world’s population, the U.S. has suffered 20 percent of global COVID-19 deaths. Tragically, most of these deaths need never have happened. They were caused primarily by the public-health equivalent of friendly fire: massive malpractice and deception by...
Source: IPS Inter Press Service - Health - October 23, 2020 Category: International Medicine & Public Health Authors: Peter Costantini Tags: Global Geopolitics Global Governance Headlines Health TerraViva United Nations Source Type: news

What Developing Countries Can Teach Us About How To Respond To a Pandemic
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post What Developing Countries Can Teach Us About How To Respond To a Pandemic appeared first on Inter Press Service. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - October 16, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health TerraViva United Nations Source Type: news